Loading...
•
Jun 30
Bruker Q2 2025 Earnings Report
Bruker reported flat revenue and a decline in profitability in Q2 2025 amid challenging demand conditions.
Key Takeaways
In Q2 2025, Bruker posted revenue of $797.4 million and flat GAAP EPS, with pressures from U.S. academic and biopharma markets. The company launched a major cost-reduction plan aiming for a stronger FY2026.
Revenue was $797.4M, down slightly from last year.
GAAP EPS held steady at $0.05; Non-GAAP EPS declined to $0.32.
Net income remained flat year-over-year at $7.6M.
Bruker initiated a cost-saving plan targeting $100–120M in annual reductions for FY2026.
Bruker
Bruker
Bruker Revenue by Segment
Bruker Revenue by Geographic Location
Revenue by Segment
Bruker BioSpin Revenue
CapyFin.comBruker CALID Revenue
CapyFin.comBruker Nano Revenue
CapyFin.comBEST Revenue
CapyFin.comRevenue by Geographic Location
United States Revenue
CapyFin.comEurope Revenue
CapyFin.comAsia Pacific Revenue
CapyFin.comOther Revenue
CapyFin.com Forward Guidance
Bruker revised its FY2025 outlook downward due to continued softness in demand, but expects margin recovery in FY2026 supported by new innovations and a cost savings program.
Positive Outlook
- FY2025 revenue forecast between $3.43B and $3.50B.
- Annual cost reductions of $100–120M planned for FY2026.
- M&A expected to contribute approximately 3.5% to revenue.
- Foreign currency tailwind of around 2.5%.
- Product innovation in proteomics and metabolomics boosts long-term positioning.
Challenges Ahead
- Organic revenue expected to decline 2–4% in FY2025.
- Non-GAAP EPS guidance lowered to $1.95–2.05, from $2.41 in FY2024.
- Constant exchange rate (CER) revenue growth projected to be flat.
- Weak demand in U.S. academic and biopharma markets remains a concern.
- Timing of demand recovery remains uncertain across key segments.
Revenue & Expenses
Visualization of income flow from segment revenue to net income